SWTX RSI Chart
Last 7 days
1.0%
Last 30 days
-3.0%
Last 90 days
42.6%
Trailing 12 Months
78.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 11.7M | 0 | 17.0M | 21.7M |
2022 | 1.9M | 3.3M | 4.7M | 6.1M |
2021 | 26.4M | 17.8M | 9.2M | 546.0K |
2020 | 0 | 0 | 2.2M | 35.0M |
2019 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 16, 2024 | pichl daniel | sold | -751,550 | 50.1033 | -15,000 | chief people officer |
Feb 16, 2024 | pichl daniel | acquired | 414,600 | 27.64 | 15,000 | chief people officer |
Feb 05, 2024 | ashar bhavesh | sold | -238,435 | 49.3245 | -4,834 | chief commercial officer |
Feb 02, 2024 | ashar bhavesh | sold | -142,976 | 44.3749 | -3,222 | chief commercial officer |
Feb 02, 2024 | pichl daniel | sold | -1,160,360 | 44.3208 | -26,181 | chief people officer |
Feb 02, 2024 | pichl daniel | acquired | 449,150 | 27.64 | 16,250 | chief people officer |
Jan 08, 2024 | cassidy james | sold (taxes) | -45,392 | 41.53 | -1,093 | chief medical officer |
Jan 08, 2024 | ashar bhavesh | sold (taxes) | -60,177 | 41.53 | -1,449 | chief commercial officer |
Jan 08, 2024 | weinstein herschel s | sold (taxes) | -100,627 | 41.53 | -2,423 | general counsel & secretary |
Jan 08, 2024 | smith l. mary | sold (taxes) | -146,809 | 41.53 | -3,535 | chief development officer |
Which funds bought or sold SWTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | added | 180 | 791 | 1,022 | -% |
Mar 21, 2024 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | new | - | 2,007,500 | 2,007,500 | 0.01% |
Mar 13, 2024 | MONECO Advisors, LLC | unchanged | - | 238,860 | 651,598 | 0.12% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 22.63 | 106,526,000 | 220,334,000 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 55.71 | 19,975,000 | 33,673,100 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | added | 14.7 | 545,178 | 1,217,530 | -% |
Feb 26, 2024 | PERCEPTIVE ADVISORS LLC | added | 28.73 | 36,287,500 | 71,439,500 | 1.59% |
Feb 22, 2024 | SIERRA SUMMIT ADVISORS LLC | new | - | 256,303 | 256,303 | 0.07% |
Feb 20, 2024 | Quarry LP | reduced | -17.02 | 32,396 | 136,875 | 0.02% |
Feb 16, 2024 | HARBOUR INVESTMENTS, INC. | sold off | -100 | -231 | - | -% |
Unveiling SpringWorks Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to SpringWorks Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
SpringWorks Therapeutics Inc News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q3 | 2019Q2 |
Revenue | -1.0% | 5,603 | 5,662 | 5,756 | 4,665 | 912 | 372 | 198 | 189 | 179 | 211 | 17,028 | 33,844 | 33.00 | 157 | 997 | 1,004 |
Operating Expenses | -100.0% | - | 83,999 | 77,699 | 78,454 | 71,740 | 69,011 | 61,469 | 55,796 | 40,895 | 47,021 | 29,756 | 23,781 | 21,592 | 19,821 | 15,329 | 14,851 |
S&GA Expenses | 28.6% | 59,836 | 46,546 | 44,175 | 40,526 | 35,673 | 30,987 | 27,366 | 26,452 | 18,029 | 14,930 | 12,381 | 8,519 | 7,669 | 6,874 | 4,584 | 3,646 |
R&D Expenses | 16.6% | 43,652 | 37,453 | 33,524 | 37,928 | 36,067 | 38,024 | 34,103 | 29,344 | 22,866 | 32,091 | 17,375 | 15,262 | 13,923 | 12,947 | 10,745 | 11,205 |
Interest Expenses | - | - | - | - | 1,571 | - | - | - | 175 | - | - | - | 333 | - | - | - | - |
Net Income | -18.7% | -94,322 | -79,437 | -73,420 | -74,178 | -72,388 | -69,050 | -61,801 | -56,072 | -41,041 | -47,010 | -29,787 | 11,272 | -21,659 | -19,893 | -16,833 | -13,847 |
Net Income Margin | 16.5% | -14.99* | -17.94* | -8.26* | -7.93* | -7.41* | -6.51* | -5.88* | -4.97* | -3.04* | -2.49* | -1.72* | - | - | - | - | - |
Free Cashflow | -11.7% | -60,403 | -54,083 | -64,795 | -55,956 | -23,132 | -41,596 | -51,075 | -47,820 | -27,264 | -33,660 | -21,149 | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Assets | 55.2% | 726 | 468 | 517 | 569 | 630 | 682 | 366 | 406 | 452 | 495 | 520 | 555 | 576 | 286 | 301 | 317 | 335 | 348 | 48.00 |
Current Assets | 15.8% | 501 | 432 | 484 | 538 | 600 | 657 | 342 | 356 | 383 | 433 | 467 | 482 | 513 | 279 | 294 | 314 | 331 | 345 | 47.00 |
Cash Equivalents | 78.1% | 176 | 99.00 | 115 | 102 | 67.00 | 477 | 70.00 | 83.00 | 105 | 94.00 | 85.00 | 96.00 | 148 | 85.00 | 227 | 312 | 328 | 344 | 46.00 |
Inventory | - | 3.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -14.2% | 18.00 | 21.00 | 18.00 | 16.00 | 14.00 | 11.00 | 9.00 | 6.00 | 3.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
Liabilities | 36.9% | 100 | 73.00 | 66.00 | 62.00 | 72.00 | 69.00 | 40.00 | 29.00 | 30.00 | 29.00 | 24.00 | 20.00 | 19.00 | 13.00 | 10.00 | 9.00 | 13.00 | 11.00 | 5.00 |
Current Liabilities | 55.5% | 78.00 | 50.00 | 42.00 | 38.00 | 51.00 | 49.00 | 35.00 | 23.00 | 30.00 | 28.00 | 23.00 | 19.00 | 18.00 | 13.00 | 10.00 | 9.00 | 12.00 | 10.00 | 4.00 |
Shareholder's Equity | 58.6% | 626 | 395 | 451 | 507 | 558 | 612 | 326 | 377 | 422 | 467 | 497 | 535 | 557 | 273 | 291 | 308 | 322 | 337 | - |
Retained Earnings | -11.8% | -895 | -800 | -721 | -643 | -569 | -495 | -423 | -354 | -292 | -236 | -195 | -148 | -118 | -129 | -108 | -88.32 | -73.03 | -56.81 | -22.45 |
Additional Paid-In Capital | 27.0% | 1,524 | 1,200 | 1,177 | 1,154 | 1,130 | 1,111 | 752 | 733 | 715 | 703 | 692 | 683 | 676 | 403 | 399 | 396 | 395 | 394 | 1.00 |
Shares Outstanding | 17.4% | 73.00 | 63.00 | 63.00 | 63.00 | 62.00 | 50.00 | 49.00 | 49.00 | 48.00 | 48.00 | 48.00 | 48.00 | - | - | - | - | - | - | - |
Float | - | - | - | 1,601 | - | - | - | 906 | - | - | - | 2,903 | - | - | - | 897 | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -24.3% | -62,705 | -50,461 | -47,811 | -61,818 | -54,200 | -19,604 | -39,071 | -48,688 | -46,316 | -26,929 | -33,528 | -21,104 | 15,066 | -14,700 | -16,159 | -16,398 | -16,063 | -11,113 | -13,091 | -7,177 | - |
Share Based Compensation | 8.5% | 25,067 | 23,098 | 22,974 | 23,395 | 18,924 | 18,518 | 18,429 | 17,094 | 11,882 | 10,712 | 8,795 | 7,055 | 3,042 | 3,043 | 2,599 | 1,350 | 950 | 788 | 648 | 723 | - |
Cashflow From Investing | -560.1% | -159,205 | 34,599 | 60,756 | 98,604 | -355,010 | 86,232 | 26,757 | 26,424 | 56,181 | 35,785 | 22,544 | -30,918 | -222,781 | -127,563 | -68,328 | -160 | -130 | -84.00 | -3,785 | -261 | - |
Cashflow From Financing | 123683.1% | 299,071 | -242 | -342 | -1,848 | 298 | 340,231 | -88.00 | 261 | 244 | 425 | 129 | 359 | 269,973 | 428 | 78.00 | 6.00 | 20.00 | 169,731 | - | 163,957 | - |
Buy Backs | -4.2% | 253 | 264 | - | - | - | 212 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Revenue: | |||
Total revenue | $ 5,447 | $ 0 | $ 0 |
Operating expenses: | |||
Cost of product revenue | 422 | 0 | 0 |
Research and development | 150,487 | 146,122 | 101,676 |
Selling, general and administrative | 197,551 | 134,552 | 71,792 |
Total operating expenses | 348,460 | 280,674 | 173,468 |
Loss from operations | (343,013) | (280,674) | (173,468) |
Interest and other income: | |||
Interest and other income, net | 22,947 | 6,147 | 546 |
Total interest and other income | 22,947 | 6,147 | 546 |
Equity method investment loss | (5,038) | (2,890) | (988) |
Net loss | $ (325,104) | $ (277,417) | $ (173,910) |
Net loss per share, basic (in usd per share) | $ (5.15) | $ (5.21) | $ (3.59) |
Net loss per share, diluted (in usd per share) | $ (5.15) | $ (5.21) | $ (3.59) |
Weighted average common shares outstanding, basic (in shares) | 63,123,936 | 53,290,528 | 48,497,790 |
Weighted average common shares outstanding, diluted (in shares) | 63,123,936 | 53,290,528 | 48,497,790 |
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | Product [Member] |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 176,053 | $ 67,490 |
Marketable securities | 303,149 | 524,722 |
Accounts receivable, net | 5,930 | 0 |
Inventory | 3,103 | 0 |
Prepaid expenses and other current assets | 12,677 | 7,548 |
Total current assets | 500,912 | 599,760 |
Long-term marketable securities | 183,386 | 4,794 |
Property and equipment, net | 17,943 | 13,571 |
Operating lease right-of-use assets | 6,144 | 4,698 |
Equity method investment | 1,955 | 4,193 |
Restricted cash | 613 | 578 |
Other assets | 14,835 | 2,648 |
Total assets | 725,788 | 630,242 |
Current liabilities: | ||
Accounts payable | 7,396 | 8,010 |
Accrued expenses | 65,569 | 39,242 |
Operating lease liabilities, current | 1,061 | 483 |
Deferred revenue, current | 4,144 | 3,314 |
Total current liabilities | 78,170 | 51,049 |
Operating lease liabilities, long-term | 5,996 | 4,768 |
Deferred revenue, long-term | 15,403 | 16,233 |
Total liabilities | 99,569 | 72,050 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2023 and December 31, 2022. | 0 | 0 |
Common stock, $0.0001 par value, 150,000,000 shares authorized, 73,620,361 and 62,453,328 shares issued and 73,486,699 and 62,423,129 shares outstanding at December 31, 2023 and December 31, 2022, respectively. | 7 | 6 |
Additional paid-in capital | 1,524,196 | 1,130,224 |
Accumulated deficit | (895,034) | (569,930) |
Treasury stock, at cost (133,662 and 30,199 shares of common stock at December 31, 2023 and December 31, 2022, respectively). | (4,141) | (1,341) |
Accumulated other comprehensive income (loss) | 1,191 | (767) |
Total stockholders’ equity | 626,219 | 558,192 |
Total liabilities and stockholders’ equity | $ 725,788 | $ 630,242 |